Mumbai: Global pharma major Lupin Limited has received approval from the United States Food and Drug Administration (USFDA) ...

Lupin receives US FDA approvals for liraglutide and Glucagon injectable products: Our Bureau, Mumbai Thursday, July 24, 2025, 12:20 Hrs [IST] Global pharma major Lupin Limited (Lu ...

The new implant contains a reservoir of glucagon that sits beneath the skin and can be activated in an emergency, with no need for injections. For individuals with Type 1 diabetes, the risk of ...

Pharmaceutical company Lupin has received approval from the US Food and Drug Administration (USFDA) to market generic diabetes drugs.

The US Food and Drug Administration (FDA) has instructed all GLP-1 drug-makers to update their warning labels to include the ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are overprescribing them and some patients are taking them in secret.

A study from Florida State University uncovers biological and behavioral consequences of weight loss underlying binge-eating in women with bulimia nervosa and related syndromes. The work is published ...

For individuals with type 1 diabetes – an autoimmune condition – maintaining stable blood sugar is a constant challenge.

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver disease and type 2 diabetes ...

Vertex Pharmaceuticals' new therapy, zimislecel, has potential to be a "functional cure," experts say. A new stem cell ...

The global glucagon-like peptide-1 (GLP-1) agonists market was valued at USD 19.70 billion in 2024, driven by the rising prevalence of type 2 diabetes and obesity across the globe. The market is ...